Comparative efficacy of modified FOLFIRINOX, gemcitabine plus capecitabine and gemcitabine plus nab-paclitaxel as adjuvant treatment for resected pancreatic cancer: a Bayeasian network meta-analysis

Victor Hugo Fonseca de Jesus and Rachel P Riechelmann

ecancer 15 1276 (2021)

Medical Oncology Department, A.C. Camargo Cancer Center, Rua Prof. Antônio Prudente 211, São Paulo SP 01509-010, Brazil

Throughout the text, please consider that the primary outcome of the PRODIGE24 trial was disease-free survival, and not overall survival.

Keywords: FOLFIRINOX, gemcitabine, capecitabine, nab-paclitaxel, adjuvant, pancreatic, cancer

Correspondence to: Victor Hugo Fonseca de Jesus

Published: 12/10/2021
Received: 23/09/2021

Publication costs for this article were supported by ecancer (UK Charity number 1176307).

Copyright: © the authors; licensee ecancermedicalscience. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Funding source

This study had no funding source.

Authors’ contributions

Victor Hugo Fonseca de Jesus: conceptualisation, methodology, data curation, data analyses, writing and visualisation; Rachel Pimenta Riechelmann: methodology, writing and visualisation.


Related Articles

Angelo Borsarelli Carvalho Brito, Tiago Cordeiro Felismino, Diego Rodrigues Mendonca e Silva, Maria Paula Curado, Lais Corsino Durant, Rodrigo Gomes Taboada, Adriane Graicer Pelosof, Alessandro Landskron Diniz, Felipe Jose Fernandez Coimbra
Dina Sweed, Shaymaa Sabry El Gammal, Shimaa Kilany, Shimaa Abdelsattar, Sara Mohamed Abd Elhamed
Muhammad Tayyab Ul-Hasan Siddiqui, Ghulam Fareed, Muhammad Rizwan Khan, Amna Riaz, Saeed Sadiq Hamid
Table of Contents
Table of Contents